Frequency, Impact and a Preclinical Study of Novel ERBB Gene Family Mutations in HER2-positive Breast Cancer

Therapeutic Advances in Medical Oncology - United States
doi 10.1177/1758835918778297
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

SAGE Publications

Related search

A Novel HER2-positive Breast Cancer Phenotype Arising From Germline TP53 Mutations

Journal of Medical Genetics
Genetics
2010English

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2012English

Relapsed Classic E-Cadherin (CDH1)-Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

Clinical Cancer Research
Cancer ResearchOncology
2013English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2012English

Increased Mortality in HER2 Positive, Oestrogen Receptor Positive Invasive Breast Cancer: A Population-Based Study

British Journal of Cancer
Cancer ResearchOncology
2010English

Brain Metastases in Asian HER2-positive Breast Cancer Patients: Anti-Her2 Treatments and Their Impact on Survival

British Journal of Cancer
Cancer ResearchOncology
2012English

Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy